EUCTR2009-013618-29-IT进行中（未招募）不适用
Open-label safety and tolerability of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years, and 1 year to less than 2 years
BOEHRINGER ING.0 个研究点目标入组 16 人开始时间: 2012年3月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Male or female children 1 to <12 years of age 2)Objective diagnosis of VTE 3)End of planned treatment course with low molecular weight heparin (LMWH) or oral anticoagulant (OAC) for VTE with INR and aPTT both within normal limits. End of planned treatment course is defined as the end of all need for anticoagulant therapy as per the standard of care at the investigational site. 4)Written informed consent provided by the patient’s parent (or legal guardian) and assent provided by the patient (if applicable) at the time of ICF signature. All informed consent / assent forms should be consistent with ICH / GCP and Local Institutional Review Board (IRB) requirements and must be obtained prior to any study procedures being performed.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 33
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Weight less than 9 kg 2) Conditions associated with an increased risk of bleeding: a) Any hemorrhagic stroke b) Major surgery in the previous month c) Planned surgery or invasive procedure in the next 30 days d) History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra- articular bleeding e) Gastrointestinal haemorrhage within the past year unless the cause has been permanently eliminated (e.g., by surgery) f) Any history of gastroduodenal ulcer disease g) Hemorrhagic disorder or bleeding diathesis h) Required concurrent treatment with another LMWH, UFH, oral anticoagulant or antiplatelet agent i) Fibrinolytic agents within 48 hours of study entry j) Uncontrolled hypertension on antihypertensive medication (systolic and/or diastolic above the upper limit of normal for age sustained over 24 h) 3) Severe renal dysfunction (eGFR < 80mL/min/1.73m2 using the Schwartz formula, refer to Appendix 10.1) or requirement for dialysis 4) Active infective endocarditis 5) Hepatic disease: a) INR >2.5 (>3.0 if on OAC) or an activated partial thromboplastin time (aPTT) >100 s or, b) Active liver disease, including known hepatitis A, B or C or, c) Persistent ALT, AST, Alk. Phos >2 x ULN 6)Females who have reached menarche with a positive pregnancy test or not using a medically accepted contraceptive method. Acceptable methods of birth control are limited to: Intra-Uterine Device (IUD); oral, implantable or injectable contraceptives and estrogen patch; double barrier method (spermacide + diaphragm); or abstinence at the discretion of the investigator. 7) Anaemia (haemoglobin <80g/L) or thrombocytopenia (platelet count <10080 x109/L). Transfusions are allowed to attain satisfactory levels. 8) Patients who have taken any prohibited / restricted medication / treatment (other than those used for planned VTE treatment) within one week of first dose of study medication. For trial restrictions please see Section 4.2.2. 9) Patients who have received an investigational drug in the past 30 days 10) Patients who are allergic / sensitive to any component of the study medication and/or solvent 11) Patients considered unreliable by the investigator concerning the requirements for followup during the study and / or compliance with study drug administration, or has any condition which in the opinion of the investigator, would not allow safe participation in the study.
研究者
相似试验
进行中（未招募）
1 期
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of age.Venous Thrombotic EventMedDRA version: 14.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2009-013618-29-ESBoehringer Ingelheim España, S.A.18
进行中（未招募）
1 期
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageVenous Thrombotic EventMedDRA version: 14.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2009-013618-29-SKBoehringer Ingelheim RCV GmbH & Co KG18
进行中（未招募）
1 期
Open-label safety and tolerability of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years, and 1 year to less than 2 years. - n.a.Venous Thrombotic EventMedDRA version: 12.0Level: LLTClassification code 10066899Term: Venous thromboembolismEUCTR2009-013618-29-FRBoehringer Ingelheim France18
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageVenous Thrombotic EventMedDRA version: 14.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2009-013618-29-LVBoehringer Ingelheim RCV GmbH & Co KG16
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate in adolescentsVenous Thrombotic EventMedDRA version: 14.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2008-006866-27-Outside-EU/EEABoehringer Ingelheim (Canada) Ltd./Ltée8